Gene therapy for age-related macular degeneration

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):106–116.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388–1398.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michel M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431.
   PubMed Web of Science ®Google Scholar
• Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119(6):1175–1183.
   PubMed Web of Science ®Google Scholar
• Maguire MG, Martin DF, Ying GS, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–1761.
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226.
   PubMed Web of Science ®Google Scholar
• Kruger Falk M, Kemp H, Sorenson TL. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol. 2013;155(1):89–95.
   PubMed Web of Science ®Google Scholar
• Rakic JM, Leys A, Brie H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol. 2013;7:1849–1858.
   PubMedGoogle Scholar
• Arevalo JF, Lasave AF, Lu L, et al. Intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: 5-year results of the pan-American Collaborative Retina Study Group. Retina. 2016;36(5):859–867.
   PubMed Web of Science ®Google Scholar
• Sengillo JD, Justus S, Tsai YT, et al. Gene and cell-based therapies for inherited retinal disorders: an update. Am J Med Genet C Semin Med Genet. 2016;172(4):349–366.
   PubMed Web of Science ®Google Scholar
• Constable IJ, Lai CM, Magno AL, et al. Gene therapy in neovascular age-related macular degeneration: three year follow-up of a phase 1 randomised dose escalation trial. Am J Ophthalmol. 2017;177:150–158.
   PubMed Web of Science ®Google Scholar
• Morral N, O’Neal W, Zhou H, et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther. 1997;8(10):1275–1286.
   PubMed Web of Science ®Google Scholar
• Gao GP, Tang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996;70(12):8934–8943.
   PubMed Web of Science ®Google Scholar
• Morral N, O’Neal W, Rice K, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci USA. 1999;96(22):12816–12821.
   PubMed Web of Science ®Google Scholar
• Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity. Hum Gene Ther. 1998;9(18):2709–2716.
   PubMed Web of Science ®Google Scholar
• Kay MA, Nakai H. Looking into the safety of AAV vectors. Nature. 2003;424(6946):251.
   PubMed Web of Science ®Google Scholar
• Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol. 2015;24:59–67.
   PubMed Web of Science ®Google Scholar
• Everson EM, Trobridge GD. Retroviral vector interactions with hematopoietic cells. Curr Opin Virol. 2016;21:41–46.
   PubMed Web of Science ®Google Scholar
• Kumar M, Keller B, Makalou N, et al. Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther. 2001;12(15):1893–1905.
   PubMed Web of Science ®Google Scholar
• Booth C, Gaspar HB, Thrasher HJ. Treating immunodeficiency through HSC gene therapy. Trends Mol Med. 2016;22(4):317–327.
   PubMed Web of Science ®Google Scholar
• Zufferey R, Dull T, Manel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873–9880.
   PubMed Web of Science ®Google Scholar
• Shaw A, Cornetta K. Design and potential of non-integrating lentiviral vectors. Biomedicines. 2014;2:14–35.
   PubMedGoogle Scholar
• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 2008;21(4):583–593.
   PubMed Web of Science ®Google Scholar
• Stieger K, Cronin T, Bennett J, et al. Adeno-associated virus mediated gene therapy for retinal degenerative diseases. Methods Mol Biol. 2011;807:179–218.
   PubMedGoogle Scholar
• Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Res. 2008;48(3):353–359.
   PubMed Web of Science ®Google Scholar
• Hareendran S, Balakrishnan B, Sen D, et al. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol. 2013;23(6):399–413.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. 2003;3(11):879–889.
   PubMed Web of Science ®Google Scholar
• Yu-Wai-Man P. Genetic manipulation for inherited neurodegenerative diseases: myth or reality? Br J Ophthalmol. 2016;100(10):1322–1331.
   PubMed Web of Science ®Google Scholar
• Cheng L, Toyoguchi M, Looney DJ, et al. Efficient gene transfer to retinal pigment epithelium cells with long-term expression. Retina. 2005;25(2):193–201.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Gene transfer for ocular neovascularization and macular edema. Gene Ther. 2012;19(2):121–126.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006;17(2):167–176.
   PubMed Web of Science ®Google Scholar
• Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188(2):253–263.
   PubMed Web of Science ®Google Scholar
• Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci. 2002;43(7):2428–2434.
   PubMed Web of Science ®Google Scholar
• Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol Med. 2002;8(7):330–334.
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Morita I, Tombran-Tink J, et al. Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF. J Cell Physiol. 2001;189(3):323–333.
   PubMed Web of Science ®Google Scholar
• Luo L, Uehara H, Zhang X, et al. Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife. 2013;2:e00324.
   PubMed Web of Science ®Google Scholar
• Lai CM, Estcourt MJ, Himbeck RP, et al. Preclinical safety evaluation of subretinal AAV2.sFlt-1 in non-human primates. Gene Ther. 2012;19(10):999–1009.
   PubMed Web of Science ®Google Scholar
• Lai CM, Brankov M, Zaknich T, et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther. 2001;12(10):1299–1310.
   PubMed Web of Science ®Google Scholar
• Lai CM, Estcourt MJ, Wikstrom M, et al. rAAV.sFlt-1 gene therapy achieves lasting reversal of retinal neovascularization in the absence of a strong immune response to the viral vector. Invest Ophthalmol Vis Sci. 2009;50(9):4279–4287.
   PubMed Web of Science ®Google Scholar
• Lai YK, Sharma S, Lai CM, et al. Virus-mediated secretion gene therapy–a potential treatment for ocular neovascularization. Adv Exp Med Biol. 2003;533:447–453.
   PubMed Web of Science ®Google Scholar
• Rakoczy EP, Lai CM, Magno AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet. 2015;386(10011):2395–2403.
   PubMed Web of Science ®Google Scholar
• Avalanche biotechnologies, inc. Announces positive top-line phase 2a results for ava-101 in wet age-related macular degeneration. Available at: http://investors.adverum.com/news-releases/news-release-details/avalanche-biotechnologies-inc-announces-positive-top-line-phase. [Last accessed 14 July 2017].
   Google Scholar
• Constable IJ, Pierce CM, Lai CM, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine. 2016;14:168–175.
   PubMed Web of Science ®Google Scholar
• Avalanche biotechnologies (aavl) will not initiate phase 2b ava-101 trial in second half of 2015. Available at: https://www.streetinsider.com/Corporate+News/Avalanche+Biotechnologies+(AAVL)+Will+Not+Initiate+Phase+2b+AVA-101+Trial+in+Second+Half+of+2015/10813292.html. [Last accessed 14 July 2017].
   Google Scholar
• Avalanche biotechnologies, inc, Corporate Presentation. May 2017. Available at: http://adverum.com/science/. [Last accessed 14 July 2017].
   Google Scholar
• Yin L, Greenberg K, Hunter JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci. 2011;52(5):2775–2783.
   PubMed Web of Science ®Google Scholar
• Heier JS, Kherani S, Desai S, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017. [Epub ahead of print]. DOI:10.1016/S0140-6736(17)30979-0.
   PubMed Web of Science ®Google Scholar
• Scaria AL, LaHalpere A, Purvis A, et al. Preliminary results of a phase 1, open-label, safety and tolerability study of a single intravitreal injection of AAV2-sFLT01 in patients with neovascular age-related macular degeneration. Mol Ther. 2016;24(Supplement 1):S98.
   Google Scholar
• Regenxbio, Corporate Presentation. May 2017. Available at: http://ir.regenxbio.com/phoenix.zhtml?c=254175&p=irol-IRHome. [Last accessed 14 July 2017].
   Google Scholar
• Maclachlan TK, Lukason M, Collins M, et al. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther. 2011;19(2):326–334.
   PubMed Web of Science ®Google Scholar
• Regenxbio programs. Available at: http://www.regenxbio.com/pages/programs/index.htm?panel=5. [Last accessed 14 July 2017].
   Google Scholar
• Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci. 2007;14(3):313–322.
   PubMed Web of Science ®Google Scholar
• Igarashi T, Miyake K, Kato K. Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther. 2003;10(3):219–226.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Lauer AK, Sohn EH, et al. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study. Hum Gene Ther. 2017;28(1):99–111.
   PubMed Web of Science ®Google Scholar
• Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–389.
   PubMed Web of Science ®Google Scholar
• Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005;308(5720):419–421.
   PubMed Web of Science ®Google Scholar
• Ambati J, Atkinson JP, Galfand BD. Immunology of age-related macular degeneration. Nat Rev Immunol. 2013;13(6):438–451.
   PubMed Web of Science ®Google Scholar
• Khandhadia S, Cipriani V, Yates JR, et al. Age-related macular degeneration and the complement system. Immunobiology. 2012;217(2):127–146.
   PubMed Web of Science ®Google Scholar
• van Lookeren Campagne M, LeCouter J, Yaspan BL, et al. Mechanisms of age-related macular degeneration and therapeutic opportunities. J Pathol. 2014;232(2):151–164.
   PubMed Web of Science ®Google Scholar
• Mullins RF, Schoo DP, Sohn EH, et al. The membrane attack complex in aging human choriocapillaris: relationship to macular degeneration and choroidal thinning. Am J Pathol. 2014;184(11):3142–3153.
   PubMed Web of Science ®Google Scholar
• Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179(3):985–992.
   PubMed Web of Science ®Google Scholar
• Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. Immunol. 1990;144:3478–3483.
   Web of Science ®Google Scholar
• Cashman SM, Ramo K, Kumar-Singh R. A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. PLoS One. 2011;6(4):e19078.
   PubMed Web of Science ®Google Scholar
• Hemera Biosciences. Available at: http://www.hemerabiosciences.com/. [Last accessed 14 July 2017]
   Google Scholar
• MeiraGTx. Available at: http://meiragtx.com/pipeline/. [Last accessed 14 July 2017]
   Google Scholar
• Applied Genetic Technologies Corporation (AGTC). Available at: https://www.agtc.com/products/macular-degeneration. [Last accessed 14 July 2017]
   Google Scholar
• Geographic Atrophy in Dry-AMD. Gensight. Available at: http://www.gensight-biologics.com/index.php?page=amd [Last accessed 14 July 2017].
   Google Scholar
• RetroSense Therpeutics. RST-001. 2017. Available at: http://retrosense.com/development.html#rst. [Last accessed 14 July 2017].
   Google Scholar
• Hutvagner G, Zamore PD. A microRNAin a multiple-turnover RNAi enzyme complex. Science. 2002;297:2056–2060.
   PubMed Web of Science ®Google Scholar
• Ruiz R, Witting SR, Saxena R, et al. Robust hepatic gene silencing for functional studies using helper-dependent adenoviral vectors. Hum Gene Ther. 2009;20(1):87–94.
   PubMed Web of Science ®Google Scholar
• Askou AL, Pournaras JA, Pihlmann M, et al. Reduction of choroidal neovascularization in mice by adeno-associated virus-delivered anti-vascular endothelial growth factor shorthairpin RNA. J Gene Med. 2012;14:632–641.
   PubMed Web of Science ®Google Scholar
• Menard C, Rezende FA, Miloudi K, et al. MicroRNA signatures in vitreous humour and plasma of patients with exudative AMD. Oncotarget. 2016;7:19171–19184.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clinical Science. 2005;109(3):227–241.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–676.
   PubMed Web of Science ®Google Scholar
• Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neuro-Signals. 2005;14(5):207–221.
   PubMedGoogle Scholar
• Ford KM, Saint-Geniez M, Walshe T, et al. Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2011;52(13):9478–9487.
   PubMed Web of Science ®Google Scholar
• Saint-Geniez M, Kurihara T, Sekiyama E, et al. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci USA. 2009;106(44):18751–18756.
   PubMed Web of Science ®Google Scholar
• Grunwald JE, Daniel E, Huang J, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–161.
   PubMed Web of Science ®Google Scholar
• Ho AC, Busbee BJ, Regillo CD, et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2014;121(11):2181–2192.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258–1267.
   PubMed Web of Science ®Google Scholar
• Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49(3):568–581.
   PubMed Web of Science ®Google Scholar
• Neufeld G, Cohen T, Shraga N, et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc Med. 2002;12(1):13–19.
   PubMed Web of Science ®Google Scholar
• Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67.
   PubMed Web of Science ®Google Scholar
• Sochor MA, Vasireddy V, Drivas TG, et al. An autogenously regulated expression system for gene therapeutic ocular applications. Sci Rep. 2015;5:17105.
   PubMed Web of Science ®Google Scholar
• Le Guiner C, Stieger K, Toromanoff A, et al. Transgene regulation using the tetracycline-inducible TetR-KRAB system after AAV-mediated gene transfer in rodents and nonhuman primates. PLoS One. 2014;9(9):e102538.
   PubMed Web of Science ®Google Scholar
• Stieger K, Le Meur G, Lasne F, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther. 2006;13(5):967–975.
   PubMed Web of Science ®Google Scholar
• O’Callaghan J, Crosbie DE, Cassidy PS, et al. Therapeutic potential of AAV-mediated MMP-3 secretion from corneal endothelium in treating glaucoma. Hum Mol Genet. 2017;26(7):1230–1246.
   PubMed Web of Science ®Google Scholar
• Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5(3):285–297.
   PubMed Web of Science ®Google Scholar
• Mitchell AM, Nicolson SC, Warischalk JK, et al. AAV’s anatomy: roadmap for optimizing vectors for translational success. Curr Gene Ther. 2010;10(5):319–340.
   PubMed Web of Science ®Google Scholar